The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies—experience from a tertiary care center in Germany

• Published in: Langenbeck's archives of surgery 2024-04, Vol.409 (1), p.113-113, Article 113
• Main Authors: Reese, Mikko, Eichelmann, Ann-Kathrin, Nowacki, Tobias M., Pascher, Andreas, Sporn, Judith C.
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cardiac Surgery; Combined Modality Therapy; Cytoreduction Surgical Procedures; General Surgery; Humans; Hyperthermia, Induced; Hyperthermic Intraperitoneal Chemotherapy; Medicine; Medicine & Public Health; Percutaneous Coronary Intervention; Peritoneal Neoplasms - pathology; Peritoneum; Quality of Life; Retrospective Studies; Survival Rate; Tertiary Care Centers; Thoracic Surgery; Traumatic Surgery; Vascular Surgery
• ISSN: 1435-2451; 1435-2451
• DOI: 10.1007/s00423-024-03309-9

Purpose Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy (PIPAC) have been introduced for the treatment of PSM which could improve the overall survival and quality of life of patients with PSM. The decision to proceed with CRS and HIPEC is often challenging due the complexity of the disease, the extent of the procedure, associated side effects, and potential risks. Here, we present our experience with CRS and HIPEC to add to the ongoing discussion about eligibility criteria, technical approach, and expected outcomes and contribute to the evolution of this powerful and promising tool in the multidisciplinary treatment of patients with primary and secondary PSM. Methods A single-center retrospective chart review was conducted and included a total of 40 patients treated with CRS and HIPEC from April 2020 to September 2022 at the University Hospital Münster Department of Surgery. All patients had histologically confirmed primary or secondary peritoneal malignancies of various primary origins. Results Our study included 22 patients with peritoneal metastases from gastric cancer (55%), 8 with pseudomyxoma peritonei (20%), 4 with mesothelioma of the peritoneum (10%), and 6 patients with PSM originating from other primary tumor locations. Median PCI at time of cytoreduction was 4 (0–25). Completeness of cytoreduction score was 0 in 37 patients (92.5%), 1 in two patients (5%), and 2 in one patient (2.5%). Median overall survival across all patients was 3.69 years. Conclusion Complete cytoreduction during CRS and HIPEC can be achieved for patients with low PCI, for patients with high PCI in low-grade malignancies, and even for patients with initially high PCI in high-grade malignancies following a significant reduction of cancer burden due to extensive preoperative treatment with PIPAC and systemic chemotherapy.